CSL's CEO highlighted that organizational complexity and global economic conditions have impacted its ability to deliver strong returns, but the company's core divisions, especially Seqirus, have shown resilience.

The company projects a modest revenue growth of 4-5% for FY2026 and plans to pay a final dividend of $1.62 per share, reflecting confidence in its strategic direction.

Australian pharmaceutical giant CSL has announced a major restructuring plan, including cutting up to 3,000 jobs and spinning off its flu vaccine division, Seqirus, into a separate ASX-listed company in 2026 to streamline operations and save approximately $500 million.

The demerger will involve combining CSL's blood plasma and iron deficiency units into one entity, while the remaining group will focus on rare and serious diseases, with former Seqirus president Gordon Naylor leading the new company.

This move is part of a broader effort to focus on high-growth areas like plasma and kidney care, with the restructuring expected to cost around $770 million pre-tax but deliver savings of $500 to $550 million over three years, which will be reinvested into priority sectors.

Despite global market volatility and challenges such as declining vaccination rates, CSL reported a strong FY2025 performance, with a 14% increase in underlying profits to $3.3 billion and revenue rising 5% to $15.5 billion.

The company also announced a FY2026 share buyback of $750 million and expects FY2026 revenue growth of 4-5%, along with a final dividend increase of 12% to $1.62 per share.

Following the restructuring announcement, CSL's share price fell over 11%, reducing its market capitalization by roughly $12 billion, reflecting investor concerns over execution risks.

Global market movements saw the Australian dollar rise 0.9% to 64.92 US cents, while gold prices dipped slightly and Brent crude oil increased, indicating mixed international economic signals.

Despite the short-term disruptions, CSL's long-term outlook remains positive, with CEO Paul McKenzie emphasizing the company's resilience and strategic focus on growth sectors.

The restructuring includes closing 22 US plasma centers and reducing the workforce by up to 15% over three years, aiming to cut costs by over half a billion dollars by fiscal year 2028.

CSL continues to face challenges from unpredictable US tariffs, with potential increases up to 250%, although the impact on US operations is expected to be limited.